refin sale forecast account
trend continu upsid consensu
refin outlook incorpor oper trend last week
top-line pre-announc includ increas precis oncolog
revenu outlook base stronger-than-expect test volum growth
reduc new clinician add cologuard roughli per quarter account
normal baselin follow one-tim step-up follow launch
collabor reduc cologuard revenu futur period
account updat assumpt new order doctor net revenu decreas
respect ep improv due mix shift higher
margin precis oncolog sale decreas
increas precis oncolog revenu test volum came
nearli forecast disclos sourc strength
magnitud upsid suggest upsid core us invas breast cancer busi
due tailorx data increas sale estim
respect
reset new doctor addit assumpt new doctor addit
cologuard estim trend first
three quarter impact collabor annual
reduc new order doctor estim
respect
adjust screen revenu growth trajectori take conserv
outlook cologuard volum growth base slower pace new order
clinician see potenti upsid outlook depend outcom
plan discuss extend partnership schedul matur
decreas estim
respect
potenti upsid merger synergi guidanc
ebitda cash flow contribut precis oncolog outlook call
stand-alone precis oncolog record ebitda impli
least synergi first year believ achiev
 redund potenti upsid suppli chain integr
continu potenti upsid consensu ep forecast
street consensu base primarili potenti merger
synergi updat revenu forecast also consensu
year price histori
exact scienc corp molecular
diagnost compani initi focu
earli detect prevent
analyst certif import disclosur see disclosur
exce target ghdx merger synergi end
insur provid coverag zero co-pay patient
econom contribut end
leverag offer acquisit genom health see
upsid consensu ep estim base
potenti upsid merger synergi target
end continu healthi uptak cologuard
visibl futur busi develop believ
strateg rational acquir addit product
sell ghdx medic oncolog distribut channel
addit granular potenti oper synergi
bolt-on acquisit provid access technolog expand
pipelin boost top line
portion laboratori oper redwood citi ca
realloc madison wi anoth low-cost locat
pipelin program make econom contribut
prior end
bolt-on transact result upsid revenu outlook
cologuard offer signific reduct cog support
commerci certain countri outsid us
compani unabl achiev expect merger synergi
cologuard fail maintain uspstf rate result potenti
one compani success commerci blood-
base colorect cancer screen test compar better
perform profil cologuard
price target base ev-to-sal analysi assum multipl pro forma estim revenu
million post-merg share outstand multipl peer group high-growth diagnost compani multipl
around due scale commerci infrastructur extend histori oper effici
risk includ merger integr issu aris purchas ghdx cologuard maintain rate
uspstf result patient receiv cologuard zero co-pay blood-bas test make stool-bas test
technolog cologuard obsolet new product adopt includ liquid biopsi take longer current forecast
compani report oppenheim co inc estim
million except per test research sale profit incom profit loss per share gain incom loss loss per share averag common analysisgross exact scienc corpor
